Old Mission Capital’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Old Mission Capital’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,319	Closed	-$271K	–	1358
2024 Q1	$271K	Hold	16,319	–	–	﹤0.01%	947
2023 Q4	$220K	Buy	+16,319	New	+$178K	﹤0.01%	1045

Other funds holding CNCR

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SWA

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Old Mission Capital's CNCR Position: Q2 2024 in Review

Old Mission Capital sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2024, closing a stake of 16,319 shares — an estimated $271K sold.

Old Mission Capital first reported a position in CNCR in Q4 2023 and held it in 2 quarters. The position peaked at $271K in Q1 2024. 13 funds tracked by Wall St. Rank hold CNCR as of Q2 2024.

Old Mission Capital reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2024 after selling out during the quarter.
Old Mission Capital sold 16,319 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2024, an estimated $271K.
Old Mission Capital first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2023 and held it in 2 quarters.
Old Mission Capital's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $271K in Q1 2024.
13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2024.

Based on Old Mission Capital's 13F filing for Q2 2024, filed 14 Aug 2024.